Showing results (581-590 of 667) with videos related to
Sort By:
Pageof 67
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of RipretinibFilip Janku, Albiruni R Abdul Razak, Ping Chi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich, Grant A McArthur, George D Demetri, et al.Clinical Sarcoma Research|March 15, 2019
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)Michael C Heinrich, Janice Patterson, Carol Beadling, et al.Blood|March 5, 2005
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of KitAmie S Corbin, Shadmehr Demehri, Ian J Griswold, et al.Leukemia|November 6, 2009
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cellsU Rix, L L Remsing Rix, A S Terker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumorsJayesh Desai, Sridhar Shankar, Michael C Heinrich, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry ResultsErik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, et al.The Lancet. Oncology|June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean-Yves Blay, César Serrano, Michael C Heinrich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudySebastian Bauer, Michael C Heinrich, Suzanne George, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 5, 2008
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 casesJerzy Lasota, Christopher L Corless, Michael C Heinrich, et al.Pageof 67